Imagine finding out that a major cause of your heart disease risk is something you can’t change with diet or exercise. For about one in five people worldwide, that’s the reality of Lipoprotein(a), also known as Lp(a). This unique particle carries cholesterol through your blood, but unlike standard LDL cholesterol, its levels are almost entirely determined by your genes. If your Lp(a) is high, it acts like a double threat: it builds up plaque in your arteries and makes blood clots more likely to form. Because it doesn’t show up on a standard lipid panel, many people walk around with this hidden risk factor without knowing it.

The good news? We now understand exactly how it works, and new treatments are finally on the horizon. Here’s what you need to know about this genetic cholesterol risk and how to manage it.

What Exactly Is Lipoprotein(a)?

Lipoprotein(a) is a genetically determined lipoprotein particle that carries cholesterol and triglycerides through the bloodstream. First identified in 1963, it has gained significant attention in cardiology because it is an independent risk factor for cardiovascular disease. Think of it as a modified version of LDL (the "bad" cholesterol). It consists of an LDL-like particle with an additional protein component called apolipoprotein(a) attached to it. This extra piece gives Lp(a) unique properties that make it particularly harmful to your heart health.

Unlike regular cholesterol, which fluctuates based on what you eat and how active you are, Lp(a) levels stay relatively stable throughout your life. Dr. Enkhmaa Byambaa, a professor at UC Davis Health, notes that Lp(a) levels are 70% to 90% genetically determined. In fact, research suggests it is more heritable than hypertension, diabetes, or obesity. This means if you have high Lp(a), it was likely passed down from your parents, not caused by late-night snacks or skipping the gym.

Why Is High Lp(a) Dangerous?

High levels of Lp(a) increase your risk of several serious conditions, including coronary artery disease, stroke, peripheral artery disease, and aortic valve stenosis. The mechanism is twofold. First, Lp(a) delivers cholesterol to arterial walls, helping to form and enlarge plaques. Second, and perhaps more dangerously, it interferes with your body’s ability to break down blood clots. The unique structure of Lp(a) allows it to attach to fibrin in clots and inhibit the natural process that dissolves them. This promotes thrombus growth, making heart attacks and strokes more likely.

Clinically, doctors use specific thresholds to assess risk. A concentration above 50 mg/dL (or 105 nmol/L) is considered clinically significant for increased cardiovascular risk. Levels above 90 mg/dL (190 nmol/L) indicate severe high risk. To put that in perspective, concentrations between 130-391 mg/dL correspond to a cardiovascular risk equivalent to that seen in individuals with familial hypercholesterolemia, a well-known genetic disorder causing very high cholesterol.

Who Should Get Tested?

Here’s the frustrating part: Lp(a) is not included in standard lipid panels. You have to specifically ask your doctor for this test. Despite this, experts increasingly recommend routine screening. Dr. Gregory Schwartz, a cardiologist at the University of Colorado, advocates for universal screening, stating that all adults should get their Lp(a) levels measured to determine their risk. This aligns with recent guidelines from multiple national and international scientific organizations.

You should definitely request a test if you fall into any of these categories:

• You have a family history of high Lp(a).
• You or a close relative had a heart attack, stroke, or other cardiovascular event at a young age (premature cardiovascular disease).
• You have been diagnosed with familial hypercholesterolemia.
• You are Black, as studies show this demographic consistently demonstrates higher Lp(a) levels than white, Hispanic, or Asian populations.
• You are a woman going through menopause, since estrogen suppresses Lp(a), and levels tend to rise as estrogen declines around age 50.

Remember, having elevated Lp(a) doesn’t mean you *will* have a heart attack. As Dr. Tsimikas from the National Heart, Lung, and Blood Institute explains, it just puts you at a higher risk. But knowing your level allows you to take proactive steps to manage that risk.

Can Diet and Exercise Lower Lp(a)?

Probably the most disappointing answer in this article: not really. Unlike LDL cholesterol, Lp(a) is not significantly affected by lifestyle modifications. Eating a Mediterranean diet, running marathons, or losing weight won’t drastically lower your Lp(a) numbers. However, this doesn’t mean lifestyle doesn’t matter. The American Heart Association emphasizes that while Lp(a) itself is stubborn, lowering your *overall* risk of heart attack and stroke is still crucial. That means eating a healthy diet, being physically active, maintaining a healthy weight, stopping tobacco use, and getting enough sleep. These factors control the other variables in your cardiovascular equation.

Treatment Options: What Works Today?

Current treatment options for elevated Lp(a) remain limited, which is why early detection and managing other risk factors are so important. Let’s look at the common medications and how they interact with Lp(a).

Statins, the cornerstone of lipid-lowering therapy, do little to lower Lp(a) and might even nudge levels up slightly. Niacin can lower Lp(a) by 20-30%, but its clinical benefit remains uncertain, and it often comes with uncomfortable side effects like flushing. So, for now, the best strategy is aggressive management of other risk factors like blood pressure and smoking status.

The Future: New Drugs on the Horizon

While current options are limited, the future looks bright. The most promising emerging therapy is a class of drugs called antisense oligonucleotides (ASOs). One such drug, pelacarsen (formerly TQJ230), showed an impressive 80% reduction in Lp(a) levels in phase 2 trials. This is a game-changer. Currently, researchers are conducting the phase 3 Lp(a) HORIZON Outcomes Trial to see if lowering Lp(a) with pelacarsen actually reduces cardiovascular events in high-risk patients. Results are expected in 2025. If successful, this could be the first evidence-based therapeutic approach specifically targeting Lp(a) reduction, transforming how we manage this common genetic risk factor.

Until then, understanding your genetic profile is key. If you suspect you might have high Lp(a), talk to your doctor about getting tested. It’s a simple blood test that could provide critical insight into your long-term heart health.